<DOC>
	<DOCNO>NCT00895713</DOCNO>
	<brief_summary>The purpose study determine treatment intramuscular hepatitis B virus immune globulin Grifols , new specific hepatitis B immune globulin , effective safe prevention hepatitis B virus recurrence orthotopic liver transplantation .</brief_summary>
	<brief_title>Efficacy Safety Intramuscular HBIG Grifols Prevention Recurrence After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>1 . Male female . 2 . Age &gt; 18 year &lt; 70 year . 3 . OLT recipient HBV infectionrelated disease &gt; 18 month inclusion clinical trial . 4 . Serum HBsAgpositive within 3 month transplantation . 5 . Serum HBsAgnegative inclusion clinical trial . 6 . Serum HbeAgnegative inclusion clinical trial . 7 . Serum HBV DNAnegative DNA PCRamplification assay ( low detection limit 102 genomes/ml ) inclusion clinical trial . 8 . Continuous interrupted prophylaxis HBIG anhepatic phase part subject clinical care . 9 . Trough serum HBsAg Ab ( HBsAg IgG ) titer ( immediately predose ) &gt; 150 I.U./l least 2 consecutive determination within last 3 month inclusion clinical trail . 10 . Signed informed consent . 1 . Serum HBsAgpositive inclusion clinical trial . 2 . Serum HBeAgpositive within 3 month transplantation . 3 . Serum HBV DNApositive standard DNA hybridisation assay ( low detection limit 105 genomes/ml ) , less sensitivity technique , within 3 month transplantation . 4 . Unknown serum HBV replication status ( data HbeAg HBV DNA ) within 3 month transplantation . 5 . Previous recurrence HBV transplant liver define serum HBV DNA positive sensitive hybridisation ( low detection limit 105 genomes/ml ) assay less sensitive technique , and/or serum HBeAgpositive , and/or serum HBsAgpositive . 6 . Retransplanted liver even reason related HBV infection . 7 . Evidence hepatocellular carcinoma transplant liver , metastatic disease , time inclusion clinical trial . 8 . Evidence graft rejection time inclusion clinical trial . 9 . Lifeexpectancy le 1 year . 10 . VHC infection . 11 . HIV type 1 type 2 infection . 12 . Acute HAV infection . 13 . Previous treatment i.m . HBIG Grifols within 3 month inclusion clinical trial . 14 . Intolerance allergy i.m . HBIG Grifols contain substance ( glycine , sodium chloride , sterile water injection , homologous human immune globulin ) . 15 . History SAEs related administration human bloodderived product . 16 . History frequent AEs , even nonserious , related administration human bloodderived product . 17 . Selective IgA deficiency Abs IgA . 18 . Platelet count &lt; 50 x 109/L . 19 . Prothrombin time ( PT ) &lt; 60 % . 20 . Activated partial thromboplastin time ( APTT ) ratio &gt; 1.5 . 21 . Any haemostatic abnormality contraindicate i.m . injection accord investigator 's judgement . 22 . Haemoglobin &lt; 11 g/dl . 23 . Alcohol drug abuse moment within 1 year inclusion clinical trial . 24 . Pregnant woman woman expect pregnant within 1 year inclusion clinical trial . 25 . Breastfeeding woman . 26 . Any severe acute chronic medical , surgical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration , may interfere interpretation study result , judgment investigator , make subject inappropriate entry clinical trial . 27 . Impossibility donate serum sample first investigational product administration . 28 . Planned treatment Ig i.m . HBIG Grifols within clinical trial period . 29 . Planned modification , clinical trial period , prophylactic regimen nucleoside analogues follow subject , , within last 3 month inclusion clinical trial . 30 . The subject previously admit clinical trial . 31 . Participation clinical trial within 3 month study inclusion . 32 . Subject 's incapacity give consent personally .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>Anti-hepatitis B antibody</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>Protective level</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Intramuscular</keyword>
</DOC>